ENERGENESIS BIOMEDICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.3 TWD | -0.57% |
|
-2.61% | -13.41% |
| May. 09 | Energenesis Biomedical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 08 | Energenesis Biomedical CO.,LTD. announced a financing transaction | CI |
| Sales 2022 | 7.35M 228K | Sales 2023 | 7.16M 222K | Capitalization | 4.59B 142M |
|---|---|---|---|---|---|
| Net income 2022 | -266M -8.23M | Net income 2023 | -260M -8.05M | EV / Sales 2022 | 324 x |
| Net cash position 2022 | 475M 14.71M | Net cash position 2023 | 691M 21.39M | EV / Sales 2023 | 545 x |
| P/E ratio 2022 |
-10.7
x | P/E ratio 2023 |
-16.7
x | Employees | 35 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.29% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.57% | ||
| 1 week | -2.61% | ||
| Current month | -0.57% | ||
| 1 month | -6.44% | ||
| 3 months | -13.12% | ||
| 6 months | -19.79% | ||
| Current year | -13.41% |
1 week
51.90
53.50
1 month
51.9056.00
Current year
51.5063.90
1 year
51.5099.50
3 years
30.9099.50
5 years
30.90102.00
10 years
28.51102.00
| Managers | Title | Age | Since |
|---|---|---|---|
Han Min Chen
FOU | Founder | - | 12-08-27 |
Pei Chao Chen
DFI | Director of Finance/CFO | - | 20-05-24 |
Yi-fang Cheng
CTO | Chief Tech/Sci/R&D Officer | - | 13-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shou Shan Wu
BRD | Director/Board Member | 74 | 19-05-05 |
Jen Yi Chiu
FOU | Founder | - | 12-08-27 |
Han Min Chen
FOU | Founder | - | 12-08-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +4.57% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 52.3 | -0.57% | 74,324 |
| 24-05-31 | 52.6 | +0.57% | 52,272 |
| 24-05-30 | 52.3 | -1.32% | 74,008 |
| 24-05-29 | 53 | +1.15% | 139,486 |
| 24-05-28 | 52.4 | 0.00% | 99,288 |
End-of-day quote Taiwan S.E., June 02, 2024
More quotes
ENERGENESIS BIOMEDICAL CO., LTD. is mainly engaged in the research and development of new drugs. The Company's main product projects include experimental service analysis and reagent sales. The Company's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
| 1st Jan change | Capi. | |
|---|---|---|
| -13.41% | 123M | |
| +48.64% | 54.63B | |
| -6.44% | 39.92B | |
| +37.07% | 38.82B | |
| +14.28% | 26.86B | |
| -11.17% | 26.22B | |
| -21.40% | 18.78B | |
| +25.64% | 12.21B | |
| +0.96% | 12.16B | |
| +27.04% | 11.94B |
- Stock Market
- Equities
- 6657 Stock
